The FDA Likelihood of Approval (LoA) for Amgen’s Nplate (romiplostim) in aplastic anaemia jumped 11 points as of 22 April, according to GlobalData’s LoA analysis. The update comes after Amgen posted positive trial results in January, which showed the vast majority of participants displayed a haematological response.

While Nplate previously had an LoA of 63%, this rose to 74% after the results, as determined via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. The Phase II/III open-label study (NCT02773290) had a primary endpoint of patients achieving any haematological response at week 27, which was met by 84% of participants. At that point, there were marked improvements in platelet response (65%), erythrocyte response (74%), neutrophil response (39%), and trilineage response (26%). Nplate was also well-tolerated, with the most common safety events being nasopharyngitis (42%), upper respiratory tract infection (26%), pyrexia (19%), headache (16%), diarrhoea (13%) and muscle spasms (13%) (Jang, JH, et al. Br J Haematol. 2021 Jan; 192(1): 190–199).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nplate was evaluated in 31 patients in Japan and Korea with aplastic anaemia who were refractory to immunosuppressive therapy (IST) and thrombocytopenia. Participants were administered with Nplate subcutaneously at a fixed dose of 10µg/kg once a week for four weeks, followed by doses of 5, 10, 15 and 20µg/kg once weekly up to 52 weeks.

Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.